# Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

> **NCT06810778** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 12 (estimated)

## Conditions studied

- T-cell-prolymphocytic Leukemia
- Cutaneous T-Cell Lymphoma Refractory

## Interventions

- **DRUG:** Duvelisib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06810778
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-02
- **Primary completion:** 2030-06-01
- **Final completion:** 2031-06-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06810778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06810778, "Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06810778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*